Fiscal Year (FY) 2023 Notice of Supplemental Funding Opportunity, 60471 [2023-18911]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 169 / Friday, September 1, 2023 / Notices
research, advocacy, and clinical practice
communities, those employed by NIH or
at institutions receiving NIH support,
and the public, on a proposed revised
mission statement. The bolded language
reflects differences between the current
and proposed mission statements.
• Current mission statement: ‘‘To
seek fundamental knowledge about the
nature and behavior of living systems
and the application of that knowledge to
enhance health, lengthen life, and
reduce illness and disability.’’
• Proposed revised mission
statement: ‘‘To seek fundamental
knowledge about the nature and
behavior of living systems and to apply
that knowledge to optimize health and
prevent or reduce illness for all people.’’
Input sought about the proposed
revised mission statement includes, but
is not limited to, the following:
• Feedback on whether the proposed
new mission statement reflects the goals
and objectives as outlined in the NIHWide Strategic Plan for Fiscal Years
2021–2025 (https://www.nih.gov/sites/
default/files/about-nih/strategic-planfy2021-2025-508.pdf).
• Suggestions for specific language
that could be added to the proposed
mission statement and why.
• Feedback on any specific language
that could be removed from the
proposed mission statement and why.
NIH encourages organizations (e.g.,
patient advocacy groups, professional
societies) to submit a single response
reflective of the views of the
organization or its membership.
Dated: August 29, 2023.
Tara A. Schwetz,
Acting Principal Deputy Director, National
Institutes of Health.
[FR Doc. 2023–18989 Filed 8–31–23; 8:45 am]
Dated: August 28, 2023.
Ann Ferrero,
Public Health Analyst.
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–18911 Filed 8–31–23; 8:45 am]
BILLING CODE 4162–20–P
Substance Abuse and Mental Health
Services Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Fiscal Year (FY) 2023 Notice of
Supplemental Funding Opportunity
Substance Abuse and Mental Health
Services Administration
Substance Abuse and Mental
Health Services Administration,
Department of Health and Human
Services (HHS).
ACTION: Notice of intent to award
supplemental funding.
lotter on DSK11XQN23PROD with NOTICES1
AGENCY:
This notice is to inform the
public that the Substance Abuse and
Mental Health Services Administration
(SAMHSA) is supporting supplemental
funding in the scope of the parent award
SUMMARY:
VerDate Sep<11>2014
17:24 Aug 31, 2023
Jkt 259001
to the 36 Rural Emergency Medical
Services Training Grant (REMS)
recipients funded under Notice of
Funding Opportunity (NOFO) TI–23–
011. These recipients have a project end
date of September 29, 2024. The
supplemental funding is to provide the
opioid antagonist medication, naloxone,
that can be used to treat respiratory
depression in suspected opioid
overdose patients, and for the
procurement of emergency equipment
used to rapidly reverse the effects of
opioid overdoses. Recipients may
receive up to $49,000 for the purchase
of naloxone and up to $49,000 for
purchasing equipment, for a total of
$98,000 per recipient.
FOR FURTHER INFORMATION CONTACT:
Humberto Carvalho, Email:
Humberto.Carvalho@samhsa.hhs.gov,
Phone: (240) 276–2974.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: Rural
Emergency Medical Services Training
TI–23–011.
Assistance Listing Number: 93.243.
Authority: The REMS Training grants
are authorized under Section 330J of the
Public Health Service Act, as amended
(42 U.S.C. 254c15).
Justification: This is not a formal
request for application. Assistance will
only be provided to the 36 REMS
recipients funded in FY 2023 funded
under Rural Emergency Medical
Services Training Grant Funding
Opportunity TI–23–011, based on the
receipt of a satisfactory application and
associated budget. The purpose of the
supplement is to further expand and
enhance REMS grant activities;
therefore, only current recipients are
eligible.
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
60471
The Department of Health and
Human Services (HHS) notifies Federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: In
accordance with section 9.19 of the
Mandatory Guidelines, a notice listing
all currently HHS-certified laboratories
and IITFs is published in the Federal
Register during the first week of each
month. If any laboratory or IITF
certification is suspended or revoked,
the laboratory or IITF will be omitted
from subsequent lists until such time as
it is restored to full certification under
the Mandatory Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
The Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
SUMMARY:
E:\FR\FM\01SEN1.SGM
01SEN1
]]>Agencies
[Federal Register Volume 88, Number 169 (Friday, September 1, 2023)]
[Notices]
[Page 60471]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-18911]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Fiscal Year (FY) 2023 Notice of Supplemental Funding Opportunity
AGENCY: Substance Abuse and Mental Health Services Administration,
Department of Health and Human Services (HHS).
ACTION: Notice of intent to award supplemental funding.
-----------------------------------------------------------------------
SUMMARY: This notice is to inform the public that the Substance Abuse
and Mental Health Services Administration (SAMHSA) is supporting
supplemental funding in the scope of the parent award to the 36 Rural
Emergency Medical Services Training Grant (REMS) recipients funded
under Notice of Funding Opportunity (NOFO) TI-23-011. These recipients
have a project end date of September 29, 2024. The supplemental funding
is to provide the opioid antagonist medication, naloxone, that can be
used to treat respiratory depression in suspected opioid overdose
patients, and for the procurement of emergency equipment used to
rapidly reverse the effects of opioid overdoses. Recipients may receive
up to $49,000 for the purchase of naloxone and up to $49,000 for
purchasing equipment, for a total of $98,000 per recipient.
FOR FURTHER INFORMATION CONTACT: Humberto Carvalho, Email:
[email protected], Phone: (240) 276-2974.
SUPPLEMENTARY INFORMATION:
Funding Opportunity Title: Rural Emergency Medical Services
Training TI-23-011.
Assistance Listing Number: 93.243.
Authority: The REMS Training grants are authorized under Section
330J of the Public Health Service Act, as amended (42 U.S.C. 254c15).
Justification: This is not a formal request for application.
Assistance will only be provided to the 36 REMS recipients funded in FY
2023 funded under Rural Emergency Medical Services Training Grant
Funding Opportunity TI-23-011, based on the receipt of a satisfactory
application and associated budget. The purpose of the supplement is to
further expand and enhance REMS grant activities; therefore, only
current recipients are eligible.
Dated: August 28, 2023.
Ann Ferrero,
Public Health Analyst.
[FR Doc. 2023-18911 Filed 8-31-23; 8:45 am]
BILLING CODE 4162-20-P
